Skip to content
Menu

About Tessellon

Where science, intelligence, and commercial strategy come together.

The Tessellon Idea

tessellate (v.) — to fit together exactly, or arrange shapes or information with no gaps.

Where mathematics meets art, there is clarity. Shapes fit together precisely, creating symmetry and structure without gaps.

That idea inspired Tessellon.

We believe complex scientific and commercial questions can be approached the same way: bring the right information together, examine it rigorously, understand how the pieces connect, and work until there are no gaps in the analysis.

This is the idea behind Tessellon.

A higher dimension of thinking.

Our History

Our Story

From complex questions to clear intelligence.

In 2006, Tessellon was founded with a simple ambition: create a clearer path through the most complex challenges in pharmaceutical and biotechnology markets.

Our founding team brought together expertise in forecasting, modeling, science, technology, mathematics, programming, and research. We had worked together within a major pharmaceutical consulting firm, developing new approaches to difficult questions and creating insights that could support better decisions.

Over time, our careers took us in different directions, but we continued to collaborate. We saw an opportunity to bring that combination of analytical rigor, scientific expertise, and practical client support to a market that needed something different.

It was time for Tessellon.

Today, that foundation has evolved from consulting into scientific intelligence and decision support, with PRECISE providing data-driven intelligence for complex questions across life sciences.

Our Vision

Where science and business come together, there should be no gaps.

Tessellon was built around the belief that the best answers emerge when scientific evidence, analytical rigor, and commercial understanding are brought together.

We work to make complex information clearer, more connected, and more useful—helping organizations move from evidence to confident decisions.

Our goal is simple: Results you can believe in.

Meet Our President & CEO

Bill Cacheris

President & CEO

Founder with 20+ years of experience in scientific intelligence, commercial strategy, and biomarker analytics. Dedicated to building transparent, defensible scientific solutions for life science organizations.

Trusted by Life Sciences Organizations

Biotechnology and pharmaceutical organizations turn to Tessellon for answers to complex scientific and commercial questions. Our work is customized to the needs of each organization—from emerging biotechnology companies to global pharmaceutical leaders across the U.S., Europe, and Asia.

  • Pfizer
  • Amgen
  • BMS
  • Merck
  • Gilead
  • Sanofi
  • Takeda
  • Novartis
  • Roche
  • AstraZeneca

Our Partners

TESSELLON PARTNER

Bridge Consulting

Commercial Strategy & Leadership Partner

Connecting commercial strategy, asset evaluation, and commercialization readiness.

Bridge and Tessellon combine commercial strategy with scientific, epidemiological, and market intelligence to help life sciences organizations make better decisions about assets and markets.

Together, we can support clients from early commercial assessment and differentiation through development planning, investment decisions, and commercialization readiness.

What Bridge Brings

  • Deep Commercial Leadership

    35+ years of senior leadership experience across strategic marketing, sales, operations, sales training, and product development.

  • Biotech Commercialization Experience

    Experience working with 100+ emerging biotech companies across development stages, including interim Chief Commercial Officer leadership for Phase III companies.

  • Revenue & Decision Intelligence

    Expertise in commercial assessment and biopharma revenue forecasting that supports portfolio prioritization, investment decisions, partnering, and development strategy.

Why This Partnership Matters

  • Commercial Strategy

    Translate scientific and clinical potential into a clear commercial strategy, from early development through launch.

  • Portfolio & Investment Decisions

    Strengthen portfolio, partnering, and investment decisions with rigorous commercial assessments, valuation, and revenue forecasting.

  • Commercialization Readiness

    Build the commercial foundation needed for launch, including strategy, organizational planning, budgeting, and execution priorities.

How We Work Together

  1. 1

    ASSESS

    Commercial Opportunity Evaluate the asset, market opportunity, competitive environment, and commercial potential.

  2. 2

    DIFFERENTIATE

    Asset Positioning Define the early differentiation and commercial positioning that can strengthen the asset's value.

  3. 3

    PLAN

    Commercial Strategy Develop the commercialization strategy, organizational requirements, investment needs, and revenue outlook.

  4. 4

    EXECUTE

    Launch Readiness Support commercialization execution, including interim commercial leadership when appropriate.

Russ

Founder, President & CEO, Bridge Consulting

Russ brings more than 35 years of senior leadership experience in strategic marketing, sales management, operations, sales training, and product development. He spent 16 years at Genentech, including a pivotal role in launching its BioOncology franchise, and has worked with more than 100 emerging biotech companies through Bridge.

As Founder, President & CEO of Bridge, Russ provides commercial leadership to emerging biotech companies from early development through commercialization, including interim Chief Commercial Officer leadership for Phase III companies.

Have a Commercial Strategy Question?

Request a Consultation →

Tessellon Partner

Signacept

Primary Market Research Partner

Connecting market insight with commercial forecasting.

Signacept is a full-service boutique insights consultancy specializing in the biopharma space, providing qualitative and quantitative primary market research. Its expertise includes scientific research, HCP and KOL interviewing, segmentation, conjoint/discrete choice modeling, brand tracking, and landscape and unmet-need assessments.

What Signacept Brings

  • Primary Market Research

    Qualitative and quantitative research across biopharma markets, including HCP and KOL research, segmentation, and landscape assessments.

  • Scientific & Research Expertise

    Scientific expertise combined with more than 25 years of market research experience.

  • Advanced Research Methods

    Expertise in conjoint/discrete choice modeling, segmentation, brand tracking, unmet-need assessment, and qualitative research.

Why This Partnership Matters

  • Integrated Market Intelligence

    Connect primary market research with Tessellon's forecasting and analytical capabilities.

  • Stronger Commercial Assessments

    Bring market evidence and quantitative modeling together to support more informed assessments.

  • Deeper Market Understanding

    Incorporate insights on patients, treatment patterns, product positioning, competition, adoption, access, and share.

How We Work Together

Signacept's primary research provides market evidence that can be integrated with Tessellon's analytical and forecasting capabilities—bringing complementary perspectives together to support more robust commercial assessments.

  1. 1

    MARKET RESEARCH

    Market Evidence Quantitative and qualitative market research provides the evidence base.

  2. 2

    MARKET INTELLIGENCE

    Patient & Market Understanding Integrate market research with relevant scientific and commercial context.

  3. 3

    FORECAST

    Commercial Forecasting Translate evidence and market assumptions into quantitative forecasts.

  4. 4

    COMMERCIAL DECISION

    Decision Support Combine market intelligence and forecasting to support commercial decisions.

Katie Palmer, PhD

Founder & Principal, Signacept

Katie Palmer, PhD brings more than 25 years of agency and client-side experience in market research and commercial insight. Her expertise combines scientific knowledge with methodological expertise to help life sciences organizations understand what matters most in their markets and make better-informed commercial decisions.

Through Signacept, Katie provides quantitative and qualitative market research, patient and market insight, segmentation, forecasting, and strategic commercial support across the life sciences industry.

Have a Market Question?

Request a Consultation →

Ready to explore what Tessellon can do for your organization?

Request a Consultation →